Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (503)	5/2/2002 2:37:30 PM
From: quidditch	Respond to of 724

Here is a snip from the FY-end report: <For the 2001 fourth quarter, net sales advanced 19 percent to a quarterly record $17,253,000 from $14,545,000 in last year's comparable quarter. Fourth-quarter net income grew to $1,836,000, or $0.27 per diluted share, from $32,000, or zero per diluted share, in the year-ago period. For the full year, net sales surged 21 percent to a record $60,294,000 from $49,864,000 one year ago. 2001 net income reached $2,211,000, or $0.33 per diluted share, compared with the net loss of $3,927,000, or $0.59 per diluted share, incurred in 2000. Last year's reported results included a $950,000 charge related to the write-off of an investment. This year's results include a $260,000 charge related to non-recurring severance costs.> The annualized revenues and earnings in Q1 fall well short of the run rates for FY02 implied by the FY01 report. Not likely seasonality, is business from the pharmas off by that much? NBSC in slower segments? Was Q4 the anomaly? By the way, GS today just upped its estimates for FSH (near to touching its 52-week high): <FSH reported Q1 EPS of $0.34, $0.02 above both our and consensus expectations. Driven by a strong performance in Domestic Distribution (sales up 17%, with EBIT 22 bps above our estimate) and lower than forecast interest expense, it was a strong quarter. While International growth continues to lag, recent restructuring is clearly evident in margin improvements. Workstation segment continues incremental improvement, w/ $109mn backlog. FSH confirmed its recently increased 2002 financial guidance of $1.66-$1.70 & provided Q2 target of $0.41- $0.43. We are adjusting our '02 EPS to $1.68 reflecting Q1 EPS upside.> quid